ReviewOncoTargets and therapy2014
Colorectal cancer in Chinese patients: current and emerging treatment options.
Review in OncoTargets and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 36 citations in OpenAlex.
- Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs.Chemical reviews · 2025Review
- Clinical presentation, treatment patterns, and outcomes of colorectal cancer patients at Tikur Anbessa Specialized Hospital in Addis Ababa, Ethiopia: A prospective cohort study.Cancer reports (Hoboken, N.J.) · 2023Article
- Hypoxia-induced miR-653 enhances colorectal cancer progression by targeting circSETD3/KLF6 axis.Journal of Cancer · 2023Article
- ERCC overexpression associated with a poor response of cT4b colorectal cancer with FOLFOX-based neoadjuvant concurrent chemoradiation.Oncology letters · 2020Article
- Paeonol exerts anti‑tumor activity against colorectal cancer cells by inducing G0/G1 phase arrest and cell apoptosis via inhibiting the Wnt/β‑catenin signaling pathway.International journal of molecular medicine · 2020Article
- Inhibition of CDK1 Reverses the Resistance of 5-Fu in Colorectal Cancer.Cancer management and research · 2020Article
- Ubiquitin-specific peptidase 22 promotes proliferation and metastasis in human colon cancer.Oncology letters · 2019Article
- PAR2 Inhibition Enhanced the Sensitivity of Colorectal Cancer Cells to 5-FU and Reduced EMT Signaling.Oncology research · 2019Article
- Clinical development of targeted and immune based anti-cancer therapies.Journal of experimental & clinical cancer research : CR · 2019Review
- STK33/ERK2 signal pathway contribute the tumorigenesis of colorectal cancer HCT15 cells.Bioscience reports · 2019Article
- Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis.Theranostics · 2019Article
- Knockdown Of TRIM31 Enhances Colorectal Cancer Radiosensitivity By Inducing DNA Damage And Activating Apoptosis.OncoTargets and therapy · 2019Article
- Overexpression of microRNA-15 increases the chemosensitivity of colon cancer cells to 5-fluorouracil and oxaliplatin by inhibiting the nuclear factor-κB signalling pathway and inducing apoptosis.Experimental and therapeutic medicine · 2018Article
- Role of serine/threonine kinase 33 methylation in colorectal cancer and its clinical significance.Oncology letters · 2018Article
- MicroRNA-1296 Facilitates Proliferation, Migration And Invasion Of Colorectal Cancer Cells By Targeting SFPQ.Journal of Cancer · 2018Article
- The pattern of KRAS mutations in metastatic colorectal cancer: a retrospective audit from Sri Lanka.BMC research notes · 2017Article
- The role of MRP1 in the multidrug resistance of colorectal cancer.Oncology letters · 2017Article
- Expression of inositol-requiring enzyme 1β is downregulated in colorectal cancer.Oncology letters · 2017Article
- Curcumin Suppresses the Colon Cancer Proliferation by Inhibiting Wnt/β-Catenin Pathways via miR-130a.Frontiers in pharmacology · 2017Article
- EZH2 mediates lidamycin-induced cellular senescence through regulating p21 expression in human colon cancer cells.Cell death & disease · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer is the second most common cancer in Hong Kong and its incidence is rising in economically developed Chinese cities, including Hong Kong and Shanghai. Several studies conducted in the People's Republic of China have characterized the unique molecular epidemiology of familial colorectal cancer syndromes and molecular biomarkers such as microsatellite instability and genetic mutations (eg, KRAS, NRAS, BRAF, PIK3CA, ERCC1) in Chinese populations. Interethnic differences in anticancer drug response and toxicity have been well described in many cancers, and this review examined the literature with regard to the tolerance of Chinese patients to commonly used chemotherapeutic regimens and targeted therapies for metastatic colorectal cancer. Studies on the pharmacogenomic differences in drug metabolizing and DNA repair enzymes between Chinese, North Asians, and Caucasian patients were also reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.